QTORIN 3.9% Rapamycin Anhydrous Gel

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsNCT06239480PVLAPhase 3Active not recruiting2026-01-14Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.